Children's Hospital is part of the UPMC family.
Be safe anytime, anywhere.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Ranked #8 Nationally by U.S. News & World Report.
The Division of Pediatric Hematology/Oncology at Children’s Hospital is the largest, most comprehensive childhood cancer and blood disease center in western Pennsylvania, eastern Ohio, and northern West Virginia.
Our experts diagnose and treat children and adolescents with all forms of cancer and blood disorders.
UPMC Children’s Hospital of Pittsburgh is a full member of the Children’s Oncology Group (COG) — the world’s largest group devoted to childhood cancer research. This allows us to enter our cancer patients in nearly 100 active clinical trials — studies of the most promising and newest cancer treatments.
On June 4, 2014, Children's Hospital of Pittsburgh Foundation announced that it has received a $2.5 million gift from the Mario Lemieux Foundation to establish a new center for rare and hard-to-treat lymphomas that is expected to benefit children and young adults from around the world. Read the full news release about the Mario Lemieux Lymphoma Center for Children and Young Adults at UPMC Children's Hospital of Pittsburgh.
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk B-Acute Lymphoblastic Leukemia or localized B-Lineage Lymphoblastic Lymphoma
Proper Protocols for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Trial for Patients with de novo Acute Myeloid Leukemia using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD
Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia using Arsenic Trioxide and All Trans-Retinoic Acid
Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma
Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors
A Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors
Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma
MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma
Treatment for Recurrent Ependymomas in Children Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod
A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
Adding the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Recurrent Unresectable Low-Grade Gliomas (LGG)
Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas
Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Gliomas
Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia, Testing Clofarabine in the Very High Risk Stratum
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
Brentuximab Vedotin in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas
Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma or Mature B-cell Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab) in Combination with GM-CSF (Sargramostim) in Patients with Recurrent Osteosarcoma
A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors
Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Peginterferon alfa-2b in Treating Young Patients with Unresectable, Sympotomatic or Life-Threatening Plexiform Neurofibromas Associated with Neurofibromatosis Type 1
A Study of Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease
Patient-Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy with Hydroxyurea in Patients with Sickle Cell Disease
Pazopanib Neoadjuvunt Trial on Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma and Ewing Sarcoma
Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Study of MK-1775 (AZD1775) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Study of Pevonedistat (MLN4924), a NEDD8-Activating Enzyme Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors, as a Single Agent and in Combination with Temozolomide and Irinotecan
Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors Including CNS Tumors
Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Biology Study of Transient Myeloproliferative Disorder in Children with Down Syndrome
Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
UPMC Children’s Hospital of Pittsburgh
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Support the hospital by making a donation online, joining our Heroes in Healing monthly donor program, or visiting our site to learn about the other ways you can give back.